Abstract
The primary risk factor for infection with members of the Klebsiella pneumoniae species complex is prior gut colonization, and infection is often caused by the colonizing strain. Despite the importance of the gut as a reservoir for infectious Klebsiella, little is known about the association between the gut microbiome and infection. To explore this relationship, we undertook a case-control study comparing the gut community structure of Klebsiella-colonized intensive care and hematology/oncology patients. Cases were Klebsiella-colonized patients infected by their colonizing strain (N = 83). Controls were Klebsiella-colonized patients that remained asymptomatic (N = 149). First, we characterized the gut community structure of Klebsiella-colonized patients agnostic to case status. Next, we determined that gut community data is useful for classifying cases and controls using machine learning models and that the gut community structure differed between cases and controls. Klebsiella relative abundance, a known risk factor for infection, had the greatest feature importance but other gut microbes were also informative. Finally, we show that integration of gut community structure with bacterial genotype or clinical variable data enhanced the ability of machine learning models to discriminate cases and controls. This study demonstrates that including gut community data with patient- and Klebsiella-derived biomarkers improves our ability to predict infection in Klebsiella-colonized patients.
Importance Colonization is generally the first step in pathogenesis for bacteria with pathogenic potential. This step provides a unique window for intervention since a given potential pathogen has yet to cause damage to its host. Moreover, intervention during the colonization stage may help alleviate the burden of therapy failure as antimicrobial resistance rises. Yet, to understand the therapeutic potential of interventions that target colonization, we must first understand the biology of colonization and if biomarkers at the colonization stage can be used to stratify infection risk. The bacterial genus Klebsiella includes many species with varying degrees of pathogenic potential. Members of the K. pneumoniae species complex have the highest pathogenic potential. Patients colonized in their gut by these bacteria are at higher risk of subsequent infection with their colonizing strain. However, we do not understand if other members of the gut microbiota can be used as a biomarker to predict infection risk. In this study, we show that the gut microbiota differs between colonized patients that develop an infection versus those that do not. Additionally, we show that integrating gut microbiota data with patient and bacterial factors improves the ability to predict infections. As we continue to explore colonization as an intervention point to prevent infections in individuals colonized by potential pathogens, we must develop effective means for predicting and stratifying infection risk.
Competing Interest Statement
KR: Dr. Rao is supported in part from an investigator-initiated grant from Merck & Co, Inc.; he has consulted for Seres Therapeutics, Inc., Rebiotix, Inc. and Summit Therapeutics, Inc. All other authors declare that they have no competing interests.
Funding Statement
This work was supported by funding from National Institution of Health (https://www.nih.gov/) grants R01AI125307 to MAB and K99 AI153483 to JV. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patient enrollment and sample collection at the University of Michigan were approved by and performed per the Institutional Review Boards (IRB) of the University of Michigan Medical School (Study number HUM00123033). This study was performed with a waiver of informed consent since the research involves no more than minimal risk to the subjects, could not practicably be carried out without the waiver, and uses discarded samples.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The sequencing data generated in this study have been deposited in the Sequence Read Archive (SRA) database under accession PRJNA789565. Deidentified human data are available under restricted access and can be obtained from MAB within 1 year upon request, pending approval from the University of Michigan Institutional Review Board. All other source data and code are available at https://github.com/jayvorn.
